Anna Berkenblit, MD, MMS

Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network

Dr. Berkenblit is currently the Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network. She brings over two decades of experience in clinical development of novel anticancer therapies in the life science industry. Most recently, she served as chief medical officer at ImmunoGen, where she led the development of ImmunoGen’s novel, wholly owned product candidates, including ElahereTM, which recently received full approval by FDA for platinum-resistant ovarian cancer. Prior to that, Dr. Berkenblit was senior vice president, clinical development at H3 Biomedicine, and vice president, head of clinical research at AVEO Oncology. She also held positions of increasing responsibility at Wyeth/Pfizer, becoming vice president, neratinib asset team leader in the Pfizer Oncology Business Unit. Over the course of her career, she has led the clinical development of oncology products spanning early testing to registration trials.

Dr. Berkenblit earned an MD from Harvard Medical School, and an MMSc in the clinical investigator training program at Harvard/MIT Health Sciences & Technology. She completed her internship and residency at Brigham and Women’s Hospital and went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center (BIDMC). Prior to transitioning to industry, she led the Phase I oncology clinical trial program at BIDMC as part of the Dana-Farber/Harvard Cancer Center.